4CPS-091 Analysis of pharmaceutical interventions related to high-risk-drugs in the emergency department

Background and importanceMedication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which are drugs that are more likely to cause serious or even fatal harm to patients when used incorrectly.Aim and objectivesDescribe the evolution o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A186-A186
Hauptverfasser: Rico-Pizarro, L, Moreno-Gutiérrez, L, Puivecino-Moreno, C, Castellanos-Clemente, Y, García-Gutiérrez, MDM, Font-Tarres, N, García-Gil, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and importanceMedication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which are drugs that are more likely to cause serious or even fatal harm to patients when used incorrectly.Aim and objectivesDescribe the evolution of pharmaceutical interventions in the ED related to HRD in two comparable time periods and evaluate the acceptance degree.Material and methodsRetrospective observational study. All interventions performed in the ED during the periods between July and December 2019 and 2020 were included. The primary endpoint was the percentage of interventions related to HRD and their acceptance percentage. Secondary endpoints were: percentage of interventions related to HRD according to therapeutic group,1 2 their acceptance percentage, and the main reasons for intervention (>15%). Interventions were recorded through the electronic prescription programme and were communicated to the responsible physician. The data were processed using Excel 2013.ResultsA total of 165/494 (33.4%) and 234/731 (32.0%) HRD interventions were performed in 2019 and 2020, respectively. The acceptance percentages were 108/165 (65.5%) and 173/234 (73.9%). The main HRD therapeutic groups on which we intervened and their acceptance percentage in the periods of 2019 and 2020, respectively, were: heparin and parenteral anticoagulants (23.6% (61.5%) and 20.1% (83.0%)), insulins (12.1% (60.0%) and 15.0% (71.4%)), oral anticoagulants (10.9% (66.7%) and 13.2% (83.9%)), opioids (8.5% (71.4%) and 7.7% (77.8%), antipsychotics (7.9% (69.2%) and 6.8% (68.8%)), diuretics (7.3% (50.0%) and 16.7% (61.5%)), sedatives (6.7% (63.6%) and 4.3% (90.0%)), antibiotics (6.1% (80.0%) and 1.3% (100%)), narrow-margin antiepileptics (4.2% (71.4%) and 5.6% (69.2%)) and other groups (15%) on the most prevalent therapeutic groups (>10%) were in the 2019 and 2020 periods, respectively: heparin and parenteral anticoagulants (need for treatment (66.7% and 57.4%)); insulins (need for treatment (60.0% and 41.2%), medication reconciliation (15.0% and 23.5%), inadequate dose (10.0% and 17.6%)); oral anticoagulants (medication reconciliation (55.6% and 41.9%), inadequate dose (11.1% and 19.4%)); diuretics (medication reconciliation (50.0% and 43.6%) and renal insufficiency (16.7% and 12.8%)).Conclusion and relevanceThe percentage of interventions related to HRD was similar in both periods; however, there
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2022-eahp.390